Ashling Wahner

The FDA has granted fast track designation to the allogeneic CAR T-cell therapy CB-012 for relapsed/refractory acute myeloid leukemia.

Charlotte Lemech, MBBS, discusses the mechanism of action of MT-302, as well as the aims of the MYE Symphony trial and its potential future implications.

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2024.

Adjuvant trastuzumab plus concurrent chemotherapy led to inferior DFS outcomes when administered for 9 weeks vs 1 year in ERBB2-positive breast cancer.

Kimberly Cannavale, MPH, discusses a study of the association between Charlson comorbidity index and complete remission in patients with ovarian cancer.

Ritu Salani, MD, discusses the development of ADCs, the potential role of selinexor, and the use of PARP inhibitors across endometrial cancer subsets.

An NDA has been submitted to the FDA for TLX101-CDx for the characterization of progressive or recurrent glioma in adult and pediatric patients.

The European Commission granted marketing authorization to frontline enfortumab vedotin plus pembrolizumab for unresectable/metastatic urothelial cancer.

The European Commission approved odronextamab for patients with relapsed/refractory FL or DLBCL who have received at least 2 prior lines of therapy.

Shipra Gandhi, MD, discusses the evolution of CDK4/6 inhibitors and ADCs across breast cancer subtypes.

Ritu Salani, MD, discusses the role of ADCs in ovarian cancer and what the future of the post-IO setting in cervical cancer management may look like.

Krishnansu S. Tewari, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.

Shipra Gandhi, MD, discusses factors influencing treatment decisions for patients with HR-positive breast cancer who have progressed on CDK4/6 inhibitors.

Shipra Gandhi, MD, highlights findings with oral SERDs in HR-positive breast cancer and options to consider after progression on CDK4/6 inhibitors.

China’s National Medical Products Administration has approved fulzerasib for the treatment of adult patients with advanced KRAS G12C–mutant NSCLC.

Katharine A. Price, MD, discusses the use of HPV-targeted immunotherapy vaccines in patients with HPV16-positive head and neck squamous cell carcinoma.

China’s National Medical Products Administration has approved enfortumab vedotin for adult patients with locally advanced or metastatic urothelial cancer.

Linda T. Vahdat, MD, discusses research with copper depletion in patients with high-risk triple-negative breast cancer.

Linda T. Vahdat, MD, discusses investigations of ADCs and targeted agents in patients with TNBC and residual disease following chemoimmunotherapy.

Ivonescimab has been granted priority review in China for the frontline treatment of patients with PD-L1–positive locally advanced or metastatic NSCLC.

The FDA has approved axatilimab for adult and pediatric patients with cGVHD who have progressed on at least 2 prior lines of systemic therapy.

The FDA has granted fast track designation to Deltacel in combination with low-dose radiation for pretreated metastatic non–small cell lung cancer.

A new drug application has been submitted to the FDA for UGN-102 inlow-grade, intermediate-risk non–muscle-invasive bladder cancer.

Linda T. Vahdat, MD, discusses the use of ADCs in metastatic TNBC and how neoadjuvant immunotherapy performs in patients with early-stage TNBC.

Tilak Sundaresan, MD, and Nicole S. Evans, MD, discuss the implications of a study evaluating reasons for non-treatment among patients with PDAC.

Enfortumab vedotin plus pembrolizumab improved survival vs chemotherapy with no QOL detriment in previously untreated metastatic urothelial cancer.

Deltacel generated early signals of clinical efficacy in patients with metastatic non–small cell lung cancer who have not responded to standard therapies.

Tilak Sundaresan, MD, and Nicole S. Evans, MD, discuss common reasons for nontreatment among patients with pancreatic cancer.

Sara M. Tolaney, MD, MPH, discusses the use of ADCs in HER2-positive breast cancer and ongoing research in this patient population.

Sara M. Tolaney, MD, MPH, discusses the HER2-positive breast cancer treatment paradigm and how standard agents may be optimized to improve outcomes.